



Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study

<u>Byoung Chul Cho</u>¹, Nicolas Girard², Maxwell B Sauder³, Jill Feldman⁴, Weimin Li⁵, Farastuk Bozorgmehr⁶, Milena Mak⁷, Janellen Smith⁸, Jairo Simoes⁹, Parthiv Mahadevia⁹, Bailey G Anderson⁹, Tonatiuh Romero⁹, Karen Xia¹⁰, George Wang¹⁰, Sean P Murphy⁹, Joshua M Bauml¹⁰, Alexander I Spira¹¹

¹Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; ²Institut du Thorax Curie-Montsouris, Paris, France and Paris Saclay University, UVSQ, Versailles, France; ³University of Toronto and Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁴EGFR Resisters, Deerfield, IL, USA; ⁵West China Hospital of Sichuan University, Chengdu, Sichuan, China; ⁶Thoraxklinik Heidelberg gGmbH, University Hospital Heidelberg, Heidelberg, Germany; ⁷Instituto do Cancer do Estado de São Paulo – Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; ⁸University of California – Irvine, Irvine, CA, USA; ⁹Janssen Research & Development, Raritan, NJ, USA; ¹⁰Janssen Research & Development, Spring House, PA, USA; ¹¹Virginia Cancer Specialists, Fairfax, VA, USA





Background

- Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity¹⁻⁴
- Lazertinib is a CNS-penetrant, third-generation EGFR-TKI⁵⁻⁶
- In MARIPOSA (ClinicalTrials.gov Identifier: NCT04487080), first-line amivantamab + lazertinib significantly improved PFS versus osimertinib in EGFR-mutated advanced NSCLC⁷
- EGFR-targeted therapies are associated with dermatologic AEs, which can impact patients' quality of life and treatment adherence, and are often treated reactively with topical/systemic corticosteroids and/or systemic antibiotics^{8,9}
- Previous studies have demonstrated that use of a prophylactic oral tetracycline antibiotic resulted in significantly fewer grade ≥2 dermatologic AEs among patients who were receiving EGFR inhibitors¹⁰
- COCOON (ClinicalTrials.gov Identifier: NCT06120140) aims to evaluate the impact of enhanced versus standard dermatologic management on the incidence of dermatologic AEs among patients receiving first-line amivantamab + lazertinib

AE, adverse event; CNS, central nervous system; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.

1. Moores SL, et al. Cancer Res. 2016;76(13):3942-3953. 2. Vijayaraghavan S, et al. Mol Cancer Ther. 2020;19(10):2044-2056. 3. Yun J, et al. Cancer Discov. 2020;10(8):1194-1209. 4. Cho BC, et al. Clin Lung Cancer. 2023;24(2):89-97. 5. Ahn M-J, et al. Lancet Oncol. 2019;20(12):1681-1690. 6. Cho BC, et al. J Thorac Oncol. 2022;17(4):558-567. 7. Cho BC, et al. N Engl J Med. 2024. doi:10.1056/NEJMoa2403614. 8. Peng Y, et al. Biosci Trends. 2019;12(6):537-552. 9. Basse C, et al. Lung Cancer. 2022;17(3):116-123. 10. Petrelli F, et al. Br J Dermatol. 2016;175(6):1166-1174.



#WCLC24 wclc2024.iaslc.org



 COCOON is a phase 2, open-label, randomized study currently enrolling patients with treatment-naïve EGFR-mutated locally advanced or metastatic NSCLC

2024 World Conference SEPTEMBER 7-10, 2024

SAN DIEGO, CA USA

- As background treatment, all patients will receive IV amivantamab + oral lazertinib
 - Prophylactic anticoagulation is mandatory for the first 4 months of treatment
- Patients in Arm A will use a digital health tool to monitor treatment compliance
- All patients will receive general skincare recommendations and will be eligible to receive additional dermatologic measures as per physician discretion

Study Design Key eligibility criteria Arm A: amivantamab + lazertinib · Locally advanced or + enhanced dermatologic management metastatic NSCLC (n=90) Treatment-naïve for advanced disease Weeks 1-12 Weeks 13-52 APAC) Documented EGFR Ex19del Topical clindamycin Oral doxycycline Prophylactic lotion 1% on scalp or minocycline or I 858R antibiotics QD before bedtime 100 mg BID · ECOG PS score of 0 or 1 1:1 randomization ; US, EU, LATAM, Paronvchia Chlorhexidine 4% Stratification factors prophylaxis on the fingernails and toenails QD Race (Asian vs non-Asian) Age (<65 years vs ≥65 years) Skin La Roche Posay Lipikar AP+M Moisturizer on the body and face at least QD moisturization (N≈180ª; IV amivantamab 1050 mg (1400 mg if ≥80 kg)

⊾

Arm B: amivantamab + lazertinib + standard dermatologic management (n=90)

COCOON (ClinicalTrials.gov Identifier: NCT06120140).

on Lung Cancer

^aPlanned enrollment is 180 patients, which is estimated to provide a power of 90%, with a 2-sided alpha of 0.05, to detect a treatment difference between Arms A and B in the incidence of grade ≥2 dermatologic AEs.

AE, adverse event; APAC, Asia-Pacific; BID, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; Ex19del, exon 19 deletion; IV, intravenous; LATAM, Latin America; NSCLC, non-small cell lung cancer; QD, once daily.

once weekly for 4 weeks:

every 2 weeks thereafter

Oral lazertinib 240 mg QD





Additional Inclusion and Exclusion Criteria

Inclusion criteria	Exclusion criteria
• ≥18 years of age	History of uncontrolled illness ^a or significant drug allergy ^b
Disease is not amenable to curative therapy	History of ILD/pneumonitis
 May have brain metastases if: all lesions were treated as clinically indicated, any definitive local therapy was completed ≥2 weeks prior to randomization, and patients are receiving no more than prednisone 10 mg (or 	History of clinically significant cardiovascular disease ^c
	Received any prior systemic treatment at any time for locally advanced stage III or metastatic stage IV disease ^d
equivalent) for treatment	 Received any prior treatment with an EGFR-TKI for metastatic or unresectable disease^e
Moderate renal impairment (eGFR >45 mL/min) is	
allowed	Active or history of leptomeningeal disease
dentific	 Active hepatitis B or C virus infection or other clinically active liver disease of infectious origin
*0 ^{1,51}	

^aIncluding, but not limited to, uncontrolled diabetes, ongoing/active infection, active bleeding diathesis, impaired oxygenation requiring continuous oxygen supplementation, and psychiatric illness or other circumstances that would limit compliance with study requirements. ^bKnown allergy, hypersensitivity, or intolerance to the excipients of amivantamab or lazertinib; to tetracyclines, doxycycline, minocycline, or their excipients; or to any component of the enhanced dermatologic management. ^cIncluding, but not limited to, deep vein thrombosis or pulmonary embolism within 1 month prior to administration of the first dose of background anticancer treatment or any of the following within 6 months prior to administration of the first dose: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome; prolonged QTc interval >480 msec or clinically significant cardia carthythmia or electrophysiologic disease; uncontrolled hypertension; congestive heart failure within 6 months of administered >12 months first dose of study treatment; pericarditis/clinically significant pericardial effusion; left ventricular ejection fraction outside of normal institutional limits during screening; and myocarditis. ^cAdjuvant/neoadjuvant/neoadjuvant therapy for stage I/II disease: adlowed if administered >12 months prior to the development of locally advanced or metastatic disease and all osimertinib toxicities are resolved prior to enrollment. eGFR, estimated glomerular filtration rate: EGFR, epidermal growth factor receptor; EX19del, exon 19 deletion; FDA, US Food and Drug Administration; ILD, interstitial lung disease; NSCLC, non-small cell lung cancer; QTc, corrected QT interval; TKI, tyrosine kinase inhibitor.








COCOON Enrollment Sites

• Patients are being enrolled at 78 sites across 11 locations







Primary objective	Primary endpoint
 Evaluate the incidence of grade ≥2 DAEIs with enhanced versus standard dermatologic management in patients with locally advanced or metastatic stages IIIB/C to IV <i>EGFR</i>-mutated NSCLC who were treated with first-line amivantamab + lazertinib DAEIs included rash, dermatitis, paronychia, skin fissures, acne, erythema, skin exfoliation, skin lesion, skin irritation, and eczema^a 	 Incidence of grade ≥2 DAEIs in the first 12 weeks after initiation of amivantamab + lazertinib treatment in Arm A versus Arm B^b
Key secondary objectives	Key secondary endpoints
Characterize dermatologic toxicity in patients who were treated with enhanced versus standard dermatologic management	 Incidence and severity of any DAEIs^b Incidence and severity of grade ≥2 DAEIs in the first 6 months^b Time to first grade ≥2^b DAEI Incidence and severity of paronychia^b Incidence and severity of scalp rash^b
 Assess the impact of enhanced versus standard dermatologic management on patients' health-related quality of life 	Change from baseline up to 12 months in PROs
Evaluate the impact of enhanced dermatologic management on amivantamab + lazertinib treatment compliance	 Frequency of dose reductions, interruptions, and discontinuations due to DAEIs Relative dose intensity of amivantamab + lazertinib

Study Objectives and Endpoints

^aPreferred terms included rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, maculopapular rash, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash papular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic, and paronychia. ^bAE severity per NCI CTCAE v5.0.

AE, adverse event; DAEI, dermatologic adverse event of interest; EGFR, epidermal growth factor receptor; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; NSCLC, non-small cell lung cancer; PRO, patient-reported outcome.





Summary

- COCOON is a phase 2, open-label, randomized study evaluating the impact of enhanced versus standard dermatologic management in patients with *EGFR*-mutated locally advanced or metastatic NSCLC who were treated with first-line amivantamab + lazertinib
- Current status: The study is currently recruiting, with a goal of 180 patients
- Registration information: This study is registered with ClinicalTrials.gov (Identifier: NCT06120140)

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer







Longer follow-up of amivantamab + lazertinib vs osimertinib in first-line *EGFR*-mutant advanced NSCLC

<u>Sunday, Sep 8 10:47-10:57am</u> (OA02.03; Gadgeel)



Patient-relevant outcomes of amivantamab + lazertinib vs osimertinib in first-line *EGFR*-mutant advanced NSCLC <u>Tuesday, Sep 10 1:55-2:00pm</u> (MA12.07; Nguyen) PALOMA-3



Other Amivantamab Presentations at WCLC 2024

Subcutaneous vs intravenous amivantamab: patient satisfaction and resource utilization results <u>Monday, Sep 9 11:07-11:17am</u>

(OA09.05; Alexander)

Preventing infusion-related reactions with intravenous amivantamab: primary results

<u>Tuesday, Sep 10 2:00-2:05pm</u> (MA12.08; Lopes)



Lazertinib vs osimertinib in first-line *EGFR*-mutant advanced NSCLC <u>Sunday, Sep 8 11:07-11:17am</u> (OA02.05; Lee)



High-risk biomarker subpopulations from patients with EGFR Ex20ins in PAPILLON

<u>Tuesday, Sep 10 1:50-1:55pm</u> (MA12.06; Goldman)



Development of a **patient-friendly lung cancer lexicon**: <u>Sunday, Sep 8 6:15-7:45pm</u> <u>(P2.16F.03; Feldman)</u>

Poster tour: Monday, Sep 9 6:45-6:53pm

Additional posters:

- PolyDamas TiP: Amivantamab + cetrelimab in advanced NSCLC: <u>Virtual ePoster (EP.12H.02; Voon)</u>
- 5-year survival estimates with 1L osimertinib for EGFR-mutant advanced NSCLC in the US: <u>Virtual ePoster (EP.12A.03; Sabari)</u>







Acknowledgments

• This study was funded by Janssen Research & Development, LLC

aterial is distributed for scientific purpt

 Medical writing assistance was provided by Lumanity Communications Inc. and funded by Janssen Global Services, LLC

